Share Twitter LinkedIn Facebook Email David Peereboom, MD, Cleveland Clinic Discusses SL-701 Phase Two Trial Study Results. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023] Immunotherapy 2 Mins Read
